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10›minute consultation
Gastro›oesophageal reflux disease
Janusz Jankowski, Roger Jones, Brendan Delaney, John Dent
A 45 year old man complains of heartburn (retrosternal
burning) and regurgitation, usually after food but also at
night, for six months. Symptoms are particularly bad
after a heavy, fatty meal. Physical straining, bending,
stooping, or lying flat also worsen the symptoms.
What issues you should cover
x Heartburn is common (7% of adults have daily and
35% monthly symptoms) and is chronic and relapsing
but usually benign. Consider why the patient has con›
sulted; many are worried about heart disease or cancer.
x In two thirds of patients, heartburn does not
progress. Those with longstanding disease ( > 5 years),
however, may develop more severe symptoms as a
result of secondary strictures or ulcers.
x In patients not receiving treatment, severity of
heartburn does not predict the presence, absence, or
severity of oesophagitis. More specific symptoms for
reflux are postural symptoms, a rising from lower to
upper sternum, and response to treatment with a pro›
ton pump inhibitor (PPI). In patients taking acid
suppressants, relief of heartburn predicts healing of
oesophagitis, allowing doses to be adjusted in initial
and long term treatment.
x No strong evidence exists to justify mandatory
Helicobacter pylori eradication in patients taking PPIs
long term. Eradication is important, however, in those
with proved peptic ulcer disease.
x Barrett’s oesophagus develops in about 5% of people
with endoscopy positive reflux disease (erosive reflux
disease); 1% of these annually develop oesophageal
adenocarcinoma. This aggressive malignancy affects
5›15 people per 100 000 population, and its incidence is
increasing. Men over 45 with at least 10 years of bother›
some heartburn are most at risk. If subsequent
endoscopy confirms Barrett’s oesophagus, long term
surveillance may be indicated, and a gastroenterologist
with an interest should guide management.
What you should do
Patient’s lifestyle—The place of non›drug measures
and antacids has not been firmly established. The
exception is raising the head of the bed, although
patients rarely do this long term. However, always give
appropriate, individualised advice about obesity, smok›
ing, alcohol, and avoidance of provocative foods.
Screening for alarm features—Refer the patient for
endoscopy if indicated (box).
A trial of acid suppressants for four weeks is appropriate
for most patients with gastro›oesophageal reflux disease,
providing prompt symptoms relief and efficient diagno›
sis. Because 50›60% of patients have no endoscopically
recognisable oesophagitis (non›erosive reflux disease),
endoscopy is an insensitive test for gastro›oesophageal
reflux disease.
Optimal dose and type of PPI—Standard dose PPI
therapy once daily is the treatment of choice and will
achieve prompt and lasting symptom relief within four
weeks in most patients. If symptoms do not disappear
completely, patients can take a second dose of PPI
before the evening meal. All PPIs have similar efficacy,
although some achieve better results in more severe
oesophagitis than others.
Laparoscopic antireflux surgery can achieve an
efficacy similar to PPIs when done in specialist centres.
However, many patients still require long term PPIs,
and surgery is associated with mortality (0.25%) not
seen with PPI therapy.
Other drugs—H2 receptor antagonists are only mod›
erately effective at standard doses, and higher and
more frequent doses offer little long term advantages.
Antacids and prokinetics are only appropriate if symp›
toms occur occasionally. In the vast majority of patients
combination therapy is less effective than increasing
the PPI dose.
Tests for more recalcitrant cases—When symptoms are
not adequately relieved, even with a twice daily PPI
(about 10% of patients with reflux), consider whether
symptoms are truly related to reflux and if the patient
is taking the treatment properly. Other more
specialised diagnostic tests, such as labelled swallow
tests, and 24 hour pH monitoring, may then be
needed.
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Indications for prompt gastroscopy
• Alarm symptoms suggesting malignancy, stricture, or
severe ulceration: dysphagia, jaundice, iron deficiency
anaemia, unintentional weight loss, or abdominal mass
• Age more than 45›55 years* with new onset
dyspepsia or continuous epigastric pain
• Non›specific or atypical symptoms not responding
to PPI therapy
• Longstanding symptoms, especially in those over
45›55,* who may be at risk of complications such as
stricture, severe oesophagitis, or Barrett’s oesophagus
*Regional differences in gastro›oesophageal cancer exist in the
United Kingdom. Use audit to determine the local threshold age
for referral
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